The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

	Fourth Quarter 2018 2017						
		2017					
Reported (GAAP)	\$	477,515	\$ 355,998				
Operational Improvement Initiatives (a)		396	329				
Acquisition Related Costs (b)		-	(194)				
Integration Related Costs (c)		84	163				
FDA Mandated Product Recall (e)		(2,325)	7,500				
Frutarom Acquisition Related Costs (h)		23,550					
Adjusted (Non-GAAP)	\$	499,220	\$ 363,796				

Reconciliation of Selling and Administrative Expenses

		Fourth Quarter					
		2017					
Reported (GAAP)	\$	249,614	\$ 141,469				
Acquisition Related Costs (b)		770	(81)				
Integration Related Costs (c)		(5,145)	(1,390)				
UK Pension Settlement Charges (f)		-	(1,882)				
Frutarom Acquisition Related Costs (h)		(39,286)					
Adjusted (Non-GAAP)	\$	205,953	\$ 138,116				

Reconciliation of Operating Profit

	Fourth Quarter					
		2018	2017			
Reported (GAAP)	\$	95,250	\$ 121,879			
Operational Improvement Initiatives (a)		396	329			
Acquisition Related Costs (b)		(770)	(113)			
Integration Related Costs (c)		5,237	1,676			
Restructuring and Other Charges, net (d)		2,249	5,528			
Gain on Sale of Assets		(742)	(64)			
FDA Mandated Product Recall (e)		(2,325)	7,500			
UK Pension Settlement Charges (f)		-	2,769			
Frutarom Acquisition Related Costs (h)		62,836				
Adjusted (Non-GAAP)	\$	162,131	\$ 139,504			

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income and EPS												
	Fourth Quarter											
		:	2018	2017								
	Net Income						Net Income					
	Income	Taxes on	Attributable		Income	Taxes on	Attributable					
	before taxes	income (j)	to IFF (k)	Diluted EPS (I)	before taxes	income (j)	to IFF	Diluted EPS				
Reported (GAAP)	\$ 66,300	\$ 50,800	\$ 13,021	\$ 0.09	\$ 115,192	\$ 155,347	\$ (40,155)	\$ (0.51)				
Operational Improvement Initiatives (a)	395	133	262	-	329	82	247	-				
Acquisition Related Costs (b)	(770)	(177)	(593)	(0.01)	(113)	(45)	(68)	-				
Integration Related Costs (c)	5,236	1,160	4,076	0.04	1,676	574	1,102	0.01				
Restructuring and Other Charges, net (d)	2,249	577	1,672	0.01	5,528	1,561	3,967	0.05				
Gain on Sale of Assets	(742)	(211)	(531)	-	(64)	(20)	(44)	-				
FDA Mandated Product Recall (e)	(2,325)	(453)	(1,872)	(0.02)	7,500	2,652	4,848	0.06				
UK Pension Settlement Charges (f)	-	-	-	-	2,769	526	2,243	0.03				
U.S. Tax Reform (g)	-	(32,847)	32,847	0.30	-	(139, 172)	139,172	1.76				
Frutarom Acquisition Related Costs (h)	63,586	12,386	51,200	0.46	-	-	-	-				
Redemption value adjustment to EPS (i)				0.03								
Adjusted (Non-GAAP)	\$ 133,929	\$ 31,368	\$ 100,082	\$ 0.89	\$ 132,817	\$ 21,505	\$ 111,312	\$ 1.40				

f Adjusted (Non-GAAP) EPS ex. Amortization	
Fourth Q	uarter
2018	2017
\$ 100,082	\$ 111,312
48,106	10,366
11,257	1,679
36,849	8,687
136,931	119,999
112,155	79,413
\$ 1.22	\$ 1.51
<u> </u>	2018 \$ 100,082 48,106 11,257 36,849 136,931 112,155

N

- (a) For 2018, represents accelerated depreciation related to a plant relocation in India. For 2017, represents accelerated depreciation and idle labor costs in Hangzhou, China.
- (b) For 2018, represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses. For 2017, represents the amortization of inventory "step-up" included in Cost of goods sold and transaction costs related to the acquisitions of Fragrance Resources and PowderPure within Selling and administrative expenses.
- (c) For 2018, represents costs related to the integration of the Frutarom acquisition. For 2017, represents costs related to the integration of the David Michael and Fragrance Resources acquisitions.
- (d) For 2018, represents severance costs related to the 2017 Productivity Program and costs associated with the termination of agent relationships in a subsidiary. For 2017, represents severance costs related to the 2017 Productivity Program.
- (e) For 2018, principally represents recoveries from our insurance in the fourth quarter. For 2017, represents management's best estimate of losses related to the previously disclosed FDA mandated recall.
- (f) Represents pension settlement charges incurred in one of the Company's UK pension plans.
- (g) For 2017, represents charges incurred related to enactment of certain Ú.S. tax legislation changes in December 2017, including \$38.6 million related to net adjustments on deferred tax assets, and \$100.6 million related to taxes on deemed repatriation of earnings. For 2018, represents additional expense based on updated repatriation plans requiring accruals for withholding taxes on deemed repatriation.
- (h) Represents transaction-related costs and expenses related to the acquisition of Frutarom. Amount primarily includes \$23.5 million of amortization for inventory"step-up" costs and \$39.2 million of transaction costs included in Selling and
- (i) Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable noncontrolling interests over their existing carrying value.(j) Except for amortization, the income tax expense (benefit) on non-GAAP adjustments is computed in accordance with
- (j) Except for amortization, the income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For fiscal year 2018, these non-GAAP adjustments were not subject to foreign tax credits or valuation allowances, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the Company's adjusted worldwide effective tax rate.
- (k) For 2018, net income is reduced by income attributable to noncontrolling interest of \$2.479M.
- (I) The sum of these items does not foot due to rounding.
- (m) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

	Year Ended December						
	2018	2017					
Reported (GAAP)	\$ 1,682,707	\$1,472,463					
Operational Improvement Initiatives (a)	1,650	1,802					
Acquisition Related Costs (b)	-	15,860					
Integration Related Costs (c)	102	480					
FDA Mandated Product Recall (h)	(7,125)	11,000					
Frutarom Acquisition Related Costs (k)	23,550						
Adjusted (Non-GAAP)	\$ 1,700,884	\$1,501,605					

Reconciliation of Selling and Administrative Expenses

	Year Ended December						
		2018		2017			
Reported (GAAP)	\$	707,461	\$	570,144			
Acquisition Related Costs (b)		1,289		(4,529)			
Integration Related Costs (c)		(6,060)		(3,258)			
Legal Charges/Credits, net (d)		-		(1,000)			
Tax Assessment (e)		-		(5,331)			
UK Pension Settlement Charges (i)		-		(1,882)			
Frutarom Acquisition Related Costs (k)		(66,082)		-			
Adjusted (Non-GAAP)	\$	636,608	\$	554,144			

Reconciliation of Operating Profit

	Year Ended December					
		2018		2017		
Reported (GAAP)	\$	583,882	\$	552,630		
Operational Improvement Initiatives (a)		2,169		1,802		
Acquisition Related Costs (b)		(1,289)		20,389		
Integration Related Costs (c)		7,188		4,179		
Legal Charges/Credits, net (d)		-		1,000		
Tax Assessment (e)		-		5,331		
Restructuring and Other Charges, net (f)		4,086		19,711		
Gain on Sale of Assets		(1,177)		(184)		
FDA Mandated Product Recall (h)		(7,125)		11,000		
UK Pension Settlement Charges (i)		-		2,769		
Frutarom Acquisition Related Costs (k)		89,632				
Adjusted (Non-GAAP)	\$	677,366	\$	618,627		

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income and EPS

	Year Ended December 31,															
		2018							2017							
		Net Income						Net Income								
	lı	Income		Income Taxes on Attributable to Diluted EPS		ı	ncome	ome Taxes on		Attributable						
	befo	ore taxes	income (m)			IFF (n)		(0)		ore taxes	income (m)		to IFF		Dilut	ed EPS
Reported (GAAP)	\$	447,757	\$	107,976	\$	337,302	\$	3.79	\$	537,045	\$	241,380	\$	295,665	\$	3.72
Operational Improvement Initiatives (a)		2,169		694		1,475		0.02		1,802		450		1,352		0.02
Acquisition Related Costs (b)		(1,289)		(311)		(978)		(0.01)		20,389		6,514		13,875		0.17
Integration Related Costs (c)		7,188		1,397		5,791		0.07		4,179		1,331		2,848		0.03
Legal Charges/Credits, net (d)		-		-		-		-		1,000		354		646		0.01
Tax Assessment (e)		-		-		-		-		5,331		1,885		3,446		0.04
Restructuring and Other Charges, net (f)		4,086		1,020		3,066		0.03		19,711		5,465		14,246		0.17
Gains on Sale of Assets		(1,177)		(352)		(825)		(0.01)		(184)		(59)		(125)		-
CTA Realization (g)		-		-		-		-		(12,217)		-		(12,217)		(0.15)
FDA Mandated Product Recall (h)		(7,125)		(1,601)		(5,524)		(0.06)		11,000		3,890		7,110		0.09
UK Pension Settlement Charges (i)		-		-		-		-		2,769		526		2,243		0.03
U.S. Tax Reform (j)		-		(25,345)		25,345		0.29		-	((139,172)		139,172		1.76
Frutarom Acquisition Related Costs (k)		155,569		28,490		127,079		1.44		-		-		-		-
Redemption value adjustment to EPS (I)		-		-		-		0.03		-		-		-		-
Adjusted (Non-GAAP)	\$	607,178	\$	111,968	\$	492,731	\$	5.58	\$	590,825	\$	122,564	\$	468,261	\$	5.89

Reconciliation of	Adjusted (Non-GAA	(P) EF	PS ex. Amortization		
			Year Ended De	ecember 31,	
Numerator			2018		2017
Adjusted (Non-GAAP) Net Income		\$	492,731		\$ 468,261
Amortization of Acquisition related Intangible Assets	75,879			34,693	
Tax impact on Amortization of Acquisition related Intangible Assets	13,962			7,181	
Amortization of Acquisition related Intangible Assets, net of tax (p)	·	-	61,917	·	27,512
Adjusted (Non-GAAP) Net Income ex. Amortization			554,648		495,773
Denominator					
Weighted average shares assuming dilution (diluted)			88,121		79,370
Adjusted (Non-GAAP) EPS ex. Amortization		\$	6.28		\$ 6.23

- (a) For 2018, represents accelerated depreciation related to a plant relocation in India and Taiwan asset write off. For 2017, represents accelerated depreciation and idle labor costs in Hangzhou, China.
- (b) For 2018, represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses. For 2017, represents the amortization of inventory "step-up" included in Cost of goods sold and transaction costs related to the acquisitions of Fragrance Resources and PowderPure within Selling and administrative expenses.
- (c) For 2018, represents costs related to the integration of the Frutarom acquisition. For 2017, represents costs related to the integration of the David Michael and Fragrance Resources acquisitions.
- (d) Represents additional charge related to litigation settlement.
- (e) Represents the reserve for payment of a tax assessment related to commercial rent for prior periods.
- (f) For 2018, represents severance costs related to the 2017 Productivity Program and costs associated with the termination of agent relationships in a subsidiary. For 2017, represents severance costs related to the 2017 Productivity
- (g) Represents the release of CTA related to the liquidation of a foreign entity
- (h) For 2018, principally represents recoveries from the supplier for the third and fourth quarter, partially offset by final payments to the customer made for the effected product in the first quarter. For 2017, represents management's best estimate of losses related to the previously disclosed FDA mandated recall.
- (i) Represents pension settlement charges incurred in one of the Company's UK pension plans.
- (j) For 2017, represents charges incurred related to enactment of certain U.S. tax legislation changes in December 2017, including \$38.6 million related to net adjustments on deferred tax assets, and \$100.6 million related to taxes on deemed repatriation of earnings. For 2018, represents additional expense based on updated repatriation plans requiring accruals for withholding taxes on deemed repatriation.
- (k) Represents transaction-related costs and expenses related to the acquisition of Frutarom. Amount primarily includes \$23.5 million of amortization for inventory "step-up" costs, \$39.4 million of bridge loan commitment fees included in Interest expense; \$34.9 million make whole payment on the Senior Notes - 2007 and \$3.9 million realized loss on a fair value hedge included in Loss on extinguishment of debt; \$12.5 million realized gain on a foreign currency derivative included in Other income; and \$66.0 million of transaction costs included in Selling and administrative expenses
- (I) Represents the adjustment to EPS related to the excess of the redemption value of certain redeemable noncontrolling interests over their existing carrying value.
- (m) Except for amortization, the income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For fiscal year 2018, these non-GAAP adjustments were not subject to foreign tax credits or valuation allowances, but to the extent that such factors are applicable to any future non-GAAP adjustments we will take such factors into consideration in calculating the tax expense (benefit). For amortization, the tax benefit has been calculated based on the Company's adjusted worldwide effective tax rate.
- (n) For 2018, net income is reduced by income attributable to noncontrolling interest of \$2.479M.
- (o) The sum of these items does not foot due to rounding.
 (p) Represents all amortization of intangible assets acquired in connection with acquisitions, net of tax.